

Artery Research

ISSN (Online): 1876-4401 ISSN (Print): 1872-9312
Journal Home Page: https://www.atlantis-press.com/journals/artres

13.7: RENAL DENERVATION IN TREATMENT RESISTANT HYPERTENSION: EFFECTS ON CORONARY FLOW RESERVE AND FOREARM DILATION CAPACITY. A RANDOMIZED, DOUBLE-BLINDED, SHAM-CONTROLLED CLINICAL TRIAL

Morten Engholm, Jannik B. Bertelsen, Ole N. Mathiassen, Henrik Vase, Jesper N. Bech, Anne P. Schroeder, Ole Lederballe, Hans Rickers, Christian D. Peters, Ulla Kampmannf, Per L. Poulsen, Sten Langfeldt, Gratien Andersen, Klavs W. Hansen, Erling B. Pederse

To cite this article: Morten Engholm, Jannik B. Bertelsen, Ole N. Mathiassen, Henrik Vase, Jesper N. Bech, Anne P. Schroeder, Ole Lederballe, Hans Rickers, Christian D. Peters, Ulla Kampmannf, Per L. Poulsen, Sten Langfeldt, Gratien Andersen, Klavs W. Hansen, Erling B. Pederse (2016) 13.7: RENAL DENERVATION IN TREATMENT RESISTANT HYPERTENSION: EFFECTS ON CORONARY FLOW RESERVE AND FOREARM DILATION CAPACITY. A RANDOMIZED, DOUBLE-BLINDED, SHAM-CONTROLLED CLINICAL TRIAL, Artery Research 16:C, 81–81, DOI: https://doi.org/10.1016/j.artres.2016.10.116

To link to this article: https://doi.org/10.1016/j.artres.2016.10.116

Published online: 7 December 2019

13.5
VENTRICULAR-ARTERIAL COUPLING DURING TREATMENT WITH BISOPROLOL AND BISIPROLOL/AMLODIPIN IN HYPERTENSIVE PATIENTS

Anna Bogomaz, Yulia Kotovskaya, Zhanna Kobalava
Peoples Friendship University of Russia, Moscow, Russia

Objective: To evaluate ventricular-arterial coupling in hypertensive patients after therapy with a beta-blocker and its fixed dose combination (FDC) with amlodipine.
Design and method: 28 patients (age 53,95±7,2, 20 males, BP 148,7±13,4/96,6±14,1 mmHg, HR 83,2±10,1 bpm) with untreated uncomplicated hypertension underwent simultaneous EchoCG and blood pressure (BP) acquisition at baseline, after 4 weeks of bisoprolol 5-10 mg monotherapy and after 8 weeks after switching to FDC bisoprolol 5-10/amlodipine 5-10 mg. Doses were titrated to reach BP <140/90 mmHg. Arterial elastance (Ea) and LV elastance (Ees) at rest were calculated as end-systolic pressure (ESP)/stroke volume (SV) and ESP/end-systolic volume (ESV). Ventricular-arterial coupling (VAC) was assessed as Ea/Ees. Mechanical efficiency of left ventricle (ELV) and peripheral arterial resistance (PAR) were evaluated also. p<0,05 was considered significant.
Results: After monotherapy with bisoprolol BP was 146,1±15,3/85,3±11,3 mmHg (p>0,05 vs baseline), HR 59,8±7,7 (p<0,05 vs baseline), after FDC 132,1±11,3/76,23±11,1 mmHg and 64,54±7,0 bpm, respectively (all p<0,05 vs baseline). Bisoprolol decreased Ees from 4,45±1,9 to 3,67±0,98 (p<0,05) whereas Ea, PAR did not change significantly. Ea/Ees increased significantly from 0,47±0,16 to 0,55±0,14 (p<0,05). Switching to bisoprolol/amlodipine FDC resulted in decrease of Ea from 1,88±0,39 at baseline and from 1,92±0,38 after bisoprolol monotherapy, PAR from 137,1±35,3 at baseline and from 128,9±36, respectively to 105,6±28. Ees did not change from that on bisoprolol, Ea/Ees (0,45±0,1) returned to baseline values. ELV did not change significantly throughout a study.
Conclusions: In hypertensive patients monotherapy with bisoprolol reduces initially increased Ees without negative effect on Ea and PAR and switching to bisoprolol/amlodipine FDC results in additional Ea reduction. Thus the study confirms potential benefits of bisoprolol/amlodipine in arterial hypertension in terms of cardiovascular functioning.

13.6
SWITCHING TO BISOPROLOL/AMLODIPINE FDC ELIMINATES ADVERSE EFFECT OF A BETA-BLOCKER ON AORTIC PULSE PRESSURE AUGMENTATION

Anna Bogomaz, Yulia Kotovskaya, Zhanna Kobalava
Peoples Friendship University of Russia, Moscow, Russia

Objective: The aim of the study was to evaluate if combination with amlodipine eliminates the adverse effect of beta-blockers on aortic pulse pressure (PP) augmentation.
Methods: 28 previously untreated non-diabetic hypertensive subjects (age 53,6±5,7 years, 19 males) where treated bisoprolol 5-10 mg, if in 4 weeks BP >140/90 mmHg amlodipine 5 mg-10 mg was added to therapy to reach BP <140/90 mmHg. Before treatment, after monotherapy and after bisoprolol+amlodipin, applanation tonometry was done. The changes were considered significant if p<0,05.
Results: At the end of the study 23 patients were treated with bisoprolol 5/amlodipine 10 mg fixed dose combination, 5 — 10/10 mg. After 4 weeks of monotherapy brachial BP decreased from 153,9±9,1/83,4±7,5 to 146,7±8,3/85,1±3,4 mmHg, HR from 79,2±4,7 to 63,5±4,7 bpm (p<0,05). At the end of the study BP was 129,1±5,6/74,3±4,9 mmHg (p<0,05 vs baseline and monotherapy period), HR 62,8±4,9 bpm (p<0,05 vs baseline). Baseline central SBP was 143,2±8,2, PP 46,810,4 mmHg, augmentation index (AI) @HR 75 bpm 20±14%, PWV 10,5±2,1 m/s. After bisoprolol monotherapy the values were, respectively, 134±7,6, PP 44,2±7,3 mmHg, 27,1±16,1%, PWV 10,0±1,6 m/s. After further 4 weeks treatment with bisoprolo+amlodipine central SBP was 119,5±5,7 (p<0,05 vs baseline), PP 41,4±6,3 mmHg (p<0,05 vs baseline), AI@HR 75 bpm 21,9±6,5 % (p<0,05 vs baseline), PWV 9,6±1,0 m/s.
Conclusion: Monotherapy with bisoprolol increases central PP augmentation. Combining with amlodipine in a single pill eliminates the adverse effect of a beta-blocker on aortic PP augmentation and results in effective reduction of central SBP.

13.7
RENAL DENERVATION IN TREATMENT RESISTANT HYPERTENSION: EFFECTS ON CORONARY FLOW RESERVE AND FOREARM DILATION CAPACITY. A RANDOMIZED, DOUBLE-BLINDED, SHAM-CONTROLLED CLINICAL TRIAL

Morten Engholm [1], Jannik B. Bertelsen [1], Ole N. Mathiassen [1], Henrik Vase [1], Jesper N. Bech [3], Anne P. Schroeder [4], Ole Lederballe [4], Hans Rickers [5], Christian D. Peters [2], Ulla Kampmannf [6], Per L. Poulsen [6], Sten Langfeldt [7], Gratien Andersen [7], Klavs W. Hansen [8], Erling B. Pedersen [3], Jens F. Lassen [1], Hans E. Boetker [1], Niels H. Buus [9], Anne Kaltoft [1], Kent L. Christensen [1]
[1]*Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark*
[2]*Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark*
[3]*University Clinic in Nephrology and Hypertension, Holstebro Hospital, Hostelbro, Denmark*
[4]*Department of Cardiology, Viborg Hospital, Viborg, Denmark*
[5]*Department of Cardiology, Randers Hospital, Randers, Denmark*
[6]*Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark*
[7]*Department of Radiology, Aarhus University Hospital, Aarhus, Denmark*
[8]*Department of Internal Medicine, Silkeborg Hospital, Silkeborg, Denmark*
[9]*Department of Nephrology, Aalborg University Hospital, Aalborg, Denmark*

Background: Microvascular impairment is well documented in hypertension. In this ReSET[1] sub-study we investigated the effects of renal sympathetic denervation (RDN) on coronary flow reserve (CFR) and coronary- and forearm minimum vascular resistance (C-Rmin and F-Rmin) in patients with resistant hypertension.
Methods: A randomised, single centre, double-blind, sham-controlled clinical trial in 58 patients with resistant hypertension randomised to RDN or SHAM. Inclusion criteria: ASBP-day > 145 mmHg following stable antihypertensive treatment and 2 weeks of compliance registration. RDN was performed with the unipolar Medtronic Flex catheter (Medtronic, California, USA). CFR and C-Rmin were determined with transthoracic Doppler echocardiography and F-Rmin with venous occlusion plethysmography at baseline and six-months follow-up.
Results: Baseline mean 24-h ambulatory BP was 111±1 mmHg (RDN, n=29) and 111±2 mmHg (SHAM, n=29). Similar reductions in MAP were seen at six-months follow up (-3.5±2.0 vs -3.2±1.8, p=0.92). Baseline CFR was 2.9±0.1 (RDN) and 2.4±0.1 (SHAM) with no significant change at follow-up (0.2±0.2 vs. -0.1±0.2, P=0.57). C-Rmin was 1.9±0.3 (RDN) and 2.7±0.6 (SHAM) (mmHg min/ml pr. 100 g LVM) and unchanged (0.3±0.5 vs. -0.4±0.8, P=0.48). F-Rmin was 3.6±0.2 (RDN) and 3.6±0.3 (SHAM) (mmHg min/ml pr. 100 ml tissue) and unchanged at follow-up (0.6±0.3 vs. 0.1±0.2, P=0.17). There was a tendency toward increased baseline LVMI in the SHAM-group (121±7 (SHAM) vs. 108±3 (RDN) g/m^2, P=0.08), but with proportional change at follow-up (-4±7 vs. 3±5, P=0.38).
Conclusion: RDN had no significant effect on CFR, C-Rmin and F-Rmin. Thus, data does not support microvascular improvement following RDN in resistant hypertension.
1. Mathiassen ON, Vase H, Bech JN, Christensen KL, Buus NH, Schroeder AP *et al*. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. *Journal of Hypertension* 2016.

13.8
VENTRICULO-VASCULAR INTERACTIONS AND THE ARTERIAL WINDKESSEL: NEW INSIGHTS FROM CARDIOVASCULAR MAGNETIC RESONANCE IMAGING BEFORE AND AFTER RENAL DENERVATION

Giovanni Biglino [1], Amy Burchell [2], Jonathan Rodrigues [2], Robert D. M. Gray [3], Emma C. Hart [2], Julian F. R. Paton [2], Nathan E. Manghat [2], Andreas Baumbach [2], Angus K. Nightingale [2]
[1]*School of Clinical Sciences, University of Bristol, UK*
[2]*CardioNomics Research Group, Bristol Heart Institute, University Hospitals Bristol NHS Foundation Trust, Bristol, UK*
[3]*School of Physiology, Pharmacology & Neuroscience, Biomedical Sciences, University of Bristol, UK*

Background: Cardiovascular magnetic resonance (CMR) imaging is considered the gold standard for the evaluation of ventricular morphology and